Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity

25 Mar 2020

Abstract excerpt

Innate immune receptors such as toll-like receptors (TLRs) provide critical molecular links between innate cells and adaptive immune responses. Here, we studied the CD40 pathway as an alternative bridge between dendritic cells (DCs) and adaptive immunity in cancer. Using an experimental design free of chemo- or radiotherapy, we found CD40 activation with agonistic antibodies (⍺CD40) produced complete tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32213589
DOI: 10.1073/pnas.1918971117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunityPMID 32213589Read ↗

CD40 agonism enhances immune checkpoint blockade and generates immunologic memory via CD4+ T cells in ERα+ mammary tumorsSemantic proximity Read ↗

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read ↗

Tregs constrain CD8 <sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapySemantic proximity Read ↗

CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic TargetingSemantic proximity Read ↗

Targeting tumor tolerance: A new hope for pancreatic cancer therapy?Semantic proximity Read ↗

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read ↗

Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.Semantic proximity Read ↗

STING Licensing of Type I Dendritic Cells Potentiates Antitumor ImmunitySemantic proximity Read ↗

Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.Semantic proximity Read ↗

IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentSemantic proximity Read ↗

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.